Pyxis Oncology Inc (NASDAQ: PYXS) is a clinical-stage biotechnology company focused on developing next-generation cancer therapies. By harnessing the power of antibody-drug conjugates (ADCs) and immuno-oncology approaches, the company aims to create targeted treatments that improve outcomes for cancer patients. With a commitment to scientific innovation and precision medicine, Pyxis Oncology is advancing a pipeline of novel therapies designed to enhance the effectiveness and safety of cancer treatments. As it progresses through clinical trials, the company remains dedicated to transforming oncology care with cutting-edge biopharmaceutical solutions.
Latest shares articles
Market Analysis: US stocks under pressure ahead of US PCE data
US stocks attempt to recover despite Trump announcing 25% tariffs on auto imports, US PCE in focus
12:27, 27 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
09:59, 11 March 2025
Nvidia shares dive as trade war fears drive tech correction
Nvidia shares plunge 30% from record highs amid trade war concerns, weakening market sentiment, and investor rotation into European and Asian stocks. Learn more about the factors driving the downturn.
11:37, 10 March 2025
Lithium Americas forecast: Third-party price target
Discover the Lithium Americas (LAC) price predictions for 2025 and beyond, with analyst price targets and more on Capital.com
13:23, 3 March 2025
Ratings and Reviews
Ratings and Reviews
